Clinical trials: Liver Neoplasm
Colorectal Cancer, Liver Metastases From Colorectal Cancer
Prospective Cohort Study on the Relationship Between Exosomal Peroxiredoxin 1 (PRDX1) and Postoperative Liver Metastasis
The occurrence of liver metastasis after curative surgery for resectable colorectal cancer is an important cause of death for patients.
- Conditions
- Colorectal Cancer, Liver Metastases From Colorectal Cancer, Pathology, Exosome
- Trial name
- NCT07177742
- Testing
- Observation
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Mu-qing Yang
Breast Cancer
Liver Safety Under Upfront Arimidex vs Tamoxifen
The primary objective is to compare ARIMIDEX (anastrozole) 1 mg once daily with Tamoxifen 20 mg once daily as adjuvant treatment in terms of: incidence of fatty liver diseases.
- Trial name
- HEART (NCT00537771)
- Testing
- Anastrozole, Tamoxifen
- Where
- 16 sites in China
- Volunteers
- 384 people
- Sponsor
- AstraZeneca
Hepatocellular Carcinoma, Portal Vein Thrombosis
Surgical Outcome of HCC With Portal Vein Tumor Thrombosis on the Basis of Risk Scoring
The goal of this multicenter retrospective cohort study is to investigate the clinical outcomes and prognostic factors after hepatic resection in patients with HCC exhibiting PVTT, and to develop a prognostic index that can be…
- Conditions
- Hepatocellular Carcinoma, Portal Vein Thrombosis, Prognosis
- Trial name
- NCT06005883
- Where
- South Korea
- Volunteers
- 332 people
- Sponsor
- Keimyung University Dongsan Medical Center
Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8
Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer
This phase I/II trial studies the side effects and how well nivolumab, fluorouracil, and interferon alpha 2b work for the treatment of fibrolamellar cancer (liver cell cancer) that cannot be removed by surgery (unresectable).
- Conditions
- Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
- Trial name
- NCT04380545
- Testing
- Fluorouracil, Nivolumab, Recombinant Interferon Alpha 2b-like Protein
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer, Liver Metastases
Alternative to Two-Stage Hepatectomy
Two-stage hepatectomy with or without portal vein embolization allows to treat multiple bilobar metastases expanding surgical indications for these patients.
- Trial name
- NCT00587756
- Testing
- One-stage ultrasound guided hepatectomy
- Where
- Italy
- Volunteers
- 19 people
- Sponsor
- University of Milan
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
This phase I/II trial tests the safety and tolerability of an experimental personalized vaccine when given by itself and with pembrolizumab in treating patients with solid tumor cancers that have spread to other places in the…
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8
- Trial name
- PNeoVCA (NCT05269381)
- Testing
- Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- Mayo Clinic
Liver Tumours, Ultrasound
Standing Position Ultrasonography: Imaging Efficacy in Detecting Liver Diaphragmatic Dome Blind Area Lesions
Objective: To compare the detection efficacy of standing, supine, and left lateral decubitus ultrasonographic scanning for space-occupying lesions ≤3cm in the liver dome "blind area" and assess the feasibility of standing…
- Conditions
- Liver Tumours, Ultrasound, Position
- Trial name
- NCT07579533
- Where
- China
- Volunteers
- 95 people
- Sponsor
- The First Hospital of Jilin University
Hepatocellular Carcinoma
Predictors of Sorafenib Response in HCC
Evaluating the nutrition status of patients with advanced HCC who received sorafenib. Using the pretreatment nutrition status and quality of life as predictors to sorafenib response
- Trial name
- NCT05967429
- Testing
- The neutrophil-to- lymphocyte ratio, Prognostic nutrition index
- Volunteers
- 80 people
- Sponsor
- Sohag University
Lung Cancer, Nonsmall Cell, Renal Cell Carcinoma
Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity
"Risk factors of Immune-ChEckpoint inhibitor MEdiated Liver, gastrointestinal, endocrine and skin Toxicity" (ICEMELT) study is a prospective multicenter cohort study, enrolling patients who are scheduled to receive (1) single…
- Conditions
- Lung Cancer, Nonsmall Cell, Renal Cell Carcinoma, Melanoma, Gastric Cancer
- Trial name
- ICEMELT (NCT04631731)
- Testing
- Blood screening, Tissue screening
- Where
- 2 sites in Australia
- Volunteers
- 200 people
- Sponsor
- Western Sydney Local Health District
Fibrolamellar Hepatocellular Carcinoma (FLC)
DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma
The primary objective of the trial is the safety and tolerability of administering a vaccine targeting the DNAJB1-PRKACA fusion kinase, in combination with nivolumab and ipilimumab in patients with unresectable or metastatic FLC…
- Trial name
- NCT04248569
- Testing
- DNAJB1-PRKACA peptide vaccine, Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
HepatoCellular Carcinoma
CHARM Hepatocellular Carcinoma MEA Study
Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed cancer and the third reason for cancer-related death worldwide.
- Trial name
- NCT07650773
- Where
- 17 sites in Egypt, Kuwait and 5 more
- Volunteers
- 4,000 people
- Sponsor
- AstraZeneca
Chronic Liver Disease (CLD), Cancer
Chronic Liver Disease and Radiation-induced Second Primary Liver Malignancy
Cancer survivors are at a high risk to develop second primary malignancy (SPM) which constitutes a serious threat for them. Radiotherapy is the cornerstone for the management of many cancers as a locoregional treatment modality.
- Conditions
- Chronic Liver Disease (CLD), Cancer, Liver Fibrosis
- Trial name
- NCT06868394
- Testing
- radiotherapy, No intervention
- Where
- Egypt
- Volunteers
- 20,846 people
- Sponsor
- Suez Canal University
Liver Transplant, Liver Cancer, Immunosuppressant
Analysis of Clinical Outcomes and Complications in Patients Received Liver Transplantation: A Retrospective Study
Liver transplantation is the last-line method for liver failure. Thomas Starzl completed the first liver transplant in 1967, liver transplantation is developing rapidly.
- Trial name
- NCT05587556
- Where
- Taiwan
- Volunteers
- 1,400 people
- Sponsor
- China Medical University Hospital
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Stereotactic Radiosurgery in Treating Patients With Liver Metastases, Lung Metastases, or Other Advanced Solid Tumors
RATIONALE: Stereotactic radiosurgery delivers x-rays directly to the tumor and may cause less damage to normal tissue. PURPOSE: Phase II trial to study the effectiveness of stereotactic radiosurgery in treating patients who have…
- Trial name
- NCT00006456
- Testing
- stereotactic radiosurgery
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Virginia Commonwealth University
Hepatic Small Vessel Neoplasm
Hepatic Small Vessel Neoplasm
Small-vessel hepatic tumor is a new tumor entity of vascular origin, described in 2016 by Gill et al, in a series of 17 patients.
- Trial name
- IMAHEP (NCT06067035)
- Testing
- Imaging
- Volunteers
- 20 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatocellular Carcinoma
Laparoscopic Surgery Versus Radiofrequency Ablation for Recurrent HCC
Hepatocellular carcinoma (HCC) is the fifth most common and the third leading cause of death from cancer worldwide1 . Hepatectomy is still the main effective treatment for HCC accompanying with well-preserved cirrhosis when liver…
- Trial name
- NCT02535117
- Testing
- Laparoscopic Surgery(LS), RFA
- Volunteers
- 216 people
- Sponsor
- Sun Yat-sen University
Rupture, Spontaneous
A New Prognostic Scoring System for Spontaneous Ruptured Hepatocellular
Develop a new scoring system for HCC patients with tumor rupture.
- Trial name
- NCT03504358
- Testing
- Liver resection
- Volunteers
- 129 people
- Sponsor
- Huazhong University of Science and Technology
Kidney Cancer, Metastatic Cancer
Ultrasound in Assessing Antiangiogenic Treatment in Patients With Advanced Kidney Cancer
RATIONALE: Diagnostic procedures, such as contrast-enhanced ultrasound, may help measure a patient's response to treatment with drugs such as sunitinib malate, sorafenib tosylate, or bevacizumab, and allow doctors to plan better…
- Trial name
- NCT01105364
- Testing
- antiangiogenesis therapy, stabilized sulphur hexafluoride microbubble-based contrast agent, imaging biomarker analysis
- Where
- France
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute, France
Liver Neoplasm, HBV Infection
Single-cell Multiomics and Spatiotemporal Omics Analyze the Mechanism of Liver Degenerative Disease
The purpose of this observational study is to employ single-cell multi-omics and spatial omics technologies to characterize the spatial and immune structures within the livers of patients with fatty liver, hepatic hemangioma…
- Conditions
- Liver Neoplasm, HBV Infection, Non-alcoholic Fatty Liver Disease NAFLD, Liver Fibrosis
- Trial name
- NCT07265544
- Testing
- Collection of Preoperative Peripheral Blood, Collection of Discarded Liver Tissue During Surgery
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Nanfang Hospital, Southern Medical University
Neoplastic Disease, Solid Tumor
Indocyanine Green (ICG) Guided Tumor Resection
This is a study to assess the ability of Indocyanine Green (ICG) to identify neoplastic disease. For many pediatric solid tumors, complete resection of the primary site and/or metastatic deposits is critical for achieving a cure.
- Trial name
- NCT04084067
- Testing
- Indocyanine Green
- Where
- United States
- Volunteers
- 215 people
- Sponsor
- St. Jude Children's Research Hospital